BioSeek and Merck join hands in small molecule drug discovery

Under the collaboration, BioSeek will apply its BioMAP Systems to evaluate Merck Serono’s small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection, and nomination of candidates for preclinical development at Merck Serono. Financial details were not disclosed.

BioMAP Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in vascular inflammation, cardiovascular and respiratory diseases, fibrosis and related clinical indications.

Michael Venuti, CEO of BioSeek, said: “BioMAP Systems should provide an important value-added tool for the evaluation of compounds in Merck Serono’s autoimmune and inflammatory disease programs, with additional applications in neurodegenerative diseases and oncology.”